Its CW-2029 – developed in collaboration with AbbVie – is an investigational, conditionally activated ADC directed towards CD71 and has demonstrated encouraging anti-tumour activity in ...

Analysis showed that 25–30% of these tumor-infiltrating neutrophils expressed the CD71 protein, which was notably absent from most of the other neutrophils outside the brain tumor. The team ...